The COCOON trial compared SOC with prophylactic management for treatment-related dermatologic events with amivantamab plus lazertinib. In this Q&A, Dr. Martin F. Dietrich explains the prophylactic regimen’s impact on effects of the skin, scalp, and nails. APP Alyson Singer offers best practices for patient education. Read more
CheckMate-816 made quite a splash at both the AACR Annual Meeting 2021 and the 2021 ASCO Annual Meeting’s virtual podium, and the accompanying article by Patrick Forde, MD, explains why. Dr. Forde, who is director of the Thoracic Oncology Clinical Research Program and associate professor of Oncology at Johns Hopkins... Read more
Platinum-based chemotherapy, given either before (neoadjuvant) or after (adjuvant) surgery for stage II and III NSCLC is associated with a 5% improvement in long-term survival. Despite consensus guidelines recommending its […] Read more
The Lung Master Protocol (Lung-MAP; S1400) was a biomarker-driven master protocol. This trial was originally designed to address the relative paucity of effective, targeted therapies in squamous cell lung cancer, […] Read more
The growth of these domestic drugs should shine a light on the lack of diversity in many international clinical trials in immunotherapy. Read more
Despite U.S. Food and Drug Administration (FDA) approvals for the addition of anti–programmed death-ligand 1 (PD-L1) therapies to a first-line combination of etoposide plus a platinum-based agent for extensive-stage small […] Read more
The U.S. National Cancer Institute (NCI) Cancer Moonshot Biobank launched in September 2020, with the aim of accelerating cancer research by creating a resource of well-annotated, longitudinal cancer biospecimens from […] Read more
The immune checkpoint inhibitors (ICIs) monotherapy has resulted in significant improvements in PFS and OS in advanced NSCLC when compared with chemotherapy alone, and it has become the standard of […] Read more
In February 2021, the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) published a joint guideline update to the 2017 ASCO guidelines regarding systemic therapy for […] Read more
Because nearly one-half of patients with advanced cancer are eligible for immune checkpoint inhibitor (ICI)–based treatment, these therapies are now in widespread clinical use.1 ICIs—whether as monotherapy, in checkpoint inhibitor […] Read more
In September 2017, the US Food and Drug Administration (FDA) approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename. Although bevacizumab-awwb is the only biosimilar […] Read more